Reason for request
Inclusion
Clinical Benefit
| Substantial |
The actual benefit of TIVICAY in the indication “treatment of Human Immunodeficiency Virus (HIV)-infected adults and adolescents above 12 years of age” is substantial in antiretroviral naïve patients and in experienced patients with prior treatment failure. |
Clinical Added Value
| moderate |
In patients who have no therapeutic options and whose virus is susceptible to dolutegravir :
The Transparency Committee considers that TIVICAY (dolutegravir), in combination with an optimised background regimen, provides a moderate improvement in actual benefit (level III) in terms of immunological and virological efficacy in therapeutic management. |
| minor |
In antiretroviral-naïve or experienced patients whose virus does not have integrase inhibitor (INI) resistance mutations :
The Transparency Committee considers that TIVICAY (dolutegravir) incombination with other antiretrovirals provides a minor improvement in actual benefit (level IV) compared with raltegravir (ISENTRESS) due to having an immunological and virological efficacy that is not inferior to that of raltegravir with a higher genetic barrier to the development of resistance and better ease of use than raltegravir (a single dose versus two daily doses in the case of raltegravir). |
See also
HAS opinions and decisions
05/03/2014
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
tEvgusJqVdGK2tua
